Joana Carvalho, PhD, managing science editor —

Endovascular embolization — a minimally invasive surgery that cuts off blood flow from a specific group of blood vessels in the body — can increase the chances of survival in babies with vein of Galen aneurysmal malformation (VGAM) and severe pulmonary hypertension (PH), a study reports. Findings from…

LIQ861, Liquidia Technologies’ proprietary inhaled dry powder formulation of the vasodilator treprostinil, improves exercise capacity and quality of life for people with pulmonary arterial hypertension (PAH), according to data from the Phase 3 INSPIRE trial. Treatment with LIQ861 also led…

When used alone or in combination with other therapies, Opsumit (macitentan) can lower the mortality risk in patients with pulmonary arterial hypertension (PAH), a study found. The study, “Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice:…

The Pulmonary Hypertension Association (PHA) is inviting the patient community to participate in its virtual fashion show, set for Aug. 1, as part of its “PHA Connects: Summer PHling.” The fashion show, which has been featured for years at the PHA’s International PH Conference and…

Janssen Korea and Johnson & Johnson Innovation have launched an initiative to help advance breakthrough innovations to improve patient care during the COVID-19 pandemic, including those that can potentially diagnose pulmonary hypertension rapidly and early. The initiative, named “Seoul Innovation QuickFire Challenge for Healthcare in the…

Sotatercept (ACE-011) leads to clinically meaningful reductions in heart strain and improvements in functional capacity in patients with pulmonary arterial hypertension (PAH), top-line data from a Phase 2 trial show. The findings were presented in an oral presentation, titled “Sotatercept for…

CAR peptide (CAR), Vascular BioSciences’ lead therapeutic peptide candidate for pulmonary hypertension (PH) and other disorders, was found to increase the efficacy of Remodulin (treprostinil) at reducing clinical signs of PH and prolonging the survival of a rat model of the disease. These preclinical findings were…

Bayer has opened its second annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a grant funding program to support clinical research projects into pulmonary hypertension (PH), particularly those focused on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The program, one of…

Obesity is linked to a lower risk of mortality in patients with pulmonary hypertension (PH), particularly among those with precapillary PH, a study found. The study, “Obesity Is Associated With Pulmonary Hypertension and Modifies Outcomes,” was published in the Journal of the American…

When given alone or in combination with other therapies, Opsumit (macitentan) leads to clinically meaningful improvements in right heart function in people with pulmonary arterial hypertension (PAH), according to data from a final analysis of a Phase 4 trial. Findings were announced in the presentation “…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CS1, Cereno Scientific’s lead therapy candidate for the treatment of pulmonary arterial hypertension (PAH). CS1 is a unique reformulation of valproic acid, an anti-seizure medication that has been used for…

The U.S. Food and Drug Administration (FDA) has accepted for review the new drug application (NDA) Liquidia Technologies submitted earlier this year requesting marketing approval of LIQ861, its proprietary inhaled dry powder formulation of treprostinil, for treating pulmonary arterial hypertension (PAH). The U.S.